超越化疗：用于淋巴瘤靶向治疗的新型药物。
Beyond chemotherapy: new agents for targeted treatment of lymphoma.
机构信息
Department of Lymphoma and Myeloma, Unit 429, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Nat Rev Clin Oncol. 2011 Feb;8(2):85-96. doi: 10.1038/nrclinonc.2010.189. Epub 2010 Dec 14.
Abstract
An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.
摘要
对癌细胞生长和存活的分子生物学以及微环境在支持包括淋巴瘤细胞在内的癌细胞存活中的作用有了更深入的了解，这导致了一些潜在治疗靶点的确定。尽管取得了这些进展，但淋巴瘤的药物开发仍然缓慢、低效且常常缺乏重点。未来的工作应集中于确定可进行治疗靶向的致癌途径的“驱动”分子缺陷，发现治疗反应的预测性生物标志物，并优先考虑有前途的药物以加速其批准。本综述总结了目前淋巴瘤新型药物的开发状况，并讨论了推动该领域前进的策略。
相似文献
1
Beyond chemotherapy: new agents for targeted treatment of lymphoma.超越化疗：用于淋巴瘤靶向治疗的新型药物。
Nat Rev Clin Oncol. 2011 Feb;8(2):85-96. doi: 10.1038/nrclinonc.2010.189. Epub 2010 Dec 14.
2
From drug discovery to biomarker-driven clinical trials in lymphoma.从药物发现到淋巴瘤的生物标志物驱动临床试验。
Nat Rev Clin Oncol. 2012 Nov;9(11):643-53. doi: 10.1038/nrclinonc.2012.156. Epub 2012 Sep 11.
3
[Malignant lymphoma].[恶性淋巴瘤]
Rinsho Ketsueki. 2016 Mar;57(3):249-59. doi: 10.11406/rinketsu.57.249.
4
Lymphoma: looking from the present to the future.淋巴瘤：从当下展望未来
Chin Clin Oncol. 2015 Mar;4(1):2. doi: 10.3978/j.issn.2304-3865.2015.03.06.
5
The emerging role of immune checkpoint inhibition in malignant lymphoma.免疫检查点抑制在恶性淋巴瘤中的新兴作用。
Haematologica. 2017 Jan;102(1):30-42. doi: 10.3324/haematol.2016.150656. Epub 2016 Nov 24.
6
New targeted therapies for malignant lymphoma based on molecular heterogeneity.基于分子异质性的恶性淋巴瘤新型靶向治疗。
Expert Rev Hematol. 2017 Jan;10(1):39-51. doi: 10.1080/17474086.2017.1268046. Epub 2016 Dec 12.
7
Pitfalls of Combining Novel Agents in Lymphoma.淋巴瘤中新型药物联合应用的陷阱。
Curr Treat Options Oncol. 2018 May 28;19(7):35. doi: 10.1007/s11864-018-0548-7.
8
[Development of mechanism-based targeted therapies for malignant lymphoma].[恶性淋巴瘤基于机制的靶向治疗的发展]
Rinsho Ketsueki. 2020;61(9):1266-1274. doi: 10.11406/rinketsu.61.1266.
9
Drug Resistance in Non-Hodgkin Lymphomas.非霍奇金淋巴瘤的耐药性。
Int J Mol Sci. 2020 Mar 18;21(6):2081. doi: 10.3390/ijms21062081.
10
Developing curcumin into a viable therapeutic for lymphoma.将姜黄素开发成一种可行的淋巴瘤治疗药物。
Expert Opin Investig Drugs. 2009 Jan;18(1):57-67. doi: 10.1517/13543780802594593.
引用本文的文献
1
Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.套细胞淋巴瘤将肿瘤相关巨噬细胞极化为M2样巨噬细胞，而M2样巨噬细胞反过来又促进肿瘤发生。
Blood Adv. 2021 Jul 27;5(14):2863-2878. doi: 10.1182/bloodadvances.2020003871.
2
Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies.建立犬 B 细胞淋巴瘤的生物发光移植瘤模型，用于监测临床前研究中的肿瘤进展和治疗反应。
PLoS One. 2018 Dec 28;13(12):e0208147. doi: 10.1371/journal.pone.0208147. eCollection 2018.
3
Extracellular Vesicles: New Players in Lymphomas.细胞外囊泡：淋巴瘤的新角色。
Int J Mol Sci. 2018 Dec 21;20(1):41. doi: 10.3390/ijms20010041.
4
Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.淋巴细胞恶性肿瘤中严重失调的信号通路及通路生物标志物的临床应用
Chronic Dis Transl Med. 2018 Mar 12;4(1):29-44. doi: 10.1016/j.cdtm.2018.02.001. eCollection 2018 Mar.
5
Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.淋巴恶性肿瘤中的致癌信号通路及基于通路的治疗生物标志物
Crit Rev Oncog. 2017;22(5-6):527-557. doi: 10.1615/CritRevOncog.2017020816.
6
Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling.蛋白酶连接素-1通过抑制音猬因子信号传导来阻止人B细胞淋巴瘤的生长。
Blood Cancer J. 2018 Feb 26;8(2):24. doi: 10.1038/s41408-018-0063-x.
7
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.JAK1/2抑制剂AZD1480和CYT387通过增加细胞凋亡和破坏细胞增殖来抑制犬B细胞淋巴瘤的生长。
J Vet Intern Med. 2017 Nov;31(6):1804-1815. doi: 10.1111/jvim.14837. Epub 2017 Sep 27.
8
The landscape of new drugs in lymphoma.淋巴瘤新药的发展概况
Nat Rev Clin Oncol. 2017 Jun;14(6):335-346. doi: 10.1038/nrclinonc.2016.205. Epub 2016 Dec 29.
9
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.双重PI3K/ERK抑制通过下调IER3诱导霍奇金淋巴瘤细胞坏死性凋亡。
Sci Rep. 2016 Oct 21;6:35745. doi: 10.1038/srep35745.
10
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.新型PI3K-δ抑制剂TGR-1202通过有丝分裂阻滞增强维布妥昔单抗诱导的霍奇金淋巴瘤细胞死亡。
Leukemia. 2016 Dec;30(12):2402-2405. doi: 10.1038/leu.2016.224. Epub 2016 Aug 8.
本文引用的文献
1
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.来那度胺治疗复发或难治性经典型霍奇金淋巴瘤的 2 期多中心研究。
Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21.
2
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.安全、药代动力学和新型免疫偶联药物奥滨尤妥珠单抗治疗 B 细胞非霍奇金淋巴瘤的初步临床活性：一项 I 期研究结果。
J Clin Oncol. 2010 Apr 20;28(12):2085-93. doi: 10.1200/JCO.2009.25.1900. Epub 2010 Mar 22.
3
mTOR signaling and drug development in cancer.mTOR 信号通路与癌症的药物研发。
Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. doi: 10.1038/nrclinonc.2010.21. Epub 2010 Mar 16.
4
An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.新疗法的 I 期研究的最佳规划、设计和实施概述。
Clin Cancer Res. 2010 Mar 15;16(6):1710-8. doi: 10.1158/1078-0432.CCR-09-1993. Epub 2010 Mar 9.
5
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.美国国立综合癌症网络（NCCN）肿瘤学临床实践指南：非霍奇金淋巴瘤
J Natl Compr Canc Netw. 2010 Mar;8(3):288-334. doi: 10.6004/jnccn.2010.0021.
6
Death receptor agonists as a targeted therapy for cancer.死亡受体激动剂作为癌症的一种靶向治疗方法。
Clin Cancer Res. 2010 Mar 15;16(6):1701-8. doi: 10.1158/1078-0432.CCR-09-1692. Epub 2010 Mar 2.
7
Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.回顾 2005 年 7 月至 2007 年 12 月期间美国食品药品监督管理局批准的肿瘤学和血液学药物产品。
J Natl Cancer Inst. 2010 Feb 24;102(4):230-43. doi: 10.1093/jnci/djp515. Epub 2010 Jan 29.
8
The PI3K pathway as drug target in human cancer.PI3K 通路作为人类癌症的药物靶点。
J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19.
9
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.复发经典型霍奇金淋巴瘤患者的新型治疗策略。
Hematology Am Soc Hematol Educ Program. 2009:507-19. doi: 10.1182/asheducation-2009.1.507.
10
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.福他替尼二钠盐抑制 Syk 在非霍奇金淋巴瘤和慢性淋巴细胞白血病中具有显著的临床活性。
Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.
Zotero 插件